S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 20.25 HKD -0.25% Market Closed
Market Cap: 11B HKD
Have any thoughts about
Shanghai Henlius Biotech Inc?
Write Note

Gross Margin
Shanghai Henlius Biotech Inc

73.2%
Current
72%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.2%
=
Gross Profit
4.1B
/
Revenue
5.6B

Gross Margin Across Competitors

Country CN
Market Cap 11B HKD
Gross Margin
73%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Shanghai Henlius Biotech Inc
Glance View

Market Cap
11B HKD
Industry
Biotechnology

Shanghai Henlius Biotech, Inc. engages in the development and production of monoclonal antibody drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,234 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The firm is also engaged in the provision of related technical services. The firm operates its businesses primarily in Mainland China and the United States.

Intrinsic Value
24.43 HKD
Undervaluation 17%
Intrinsic Value
Price
S

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.2%
=
Gross Profit
4.1B
/
Revenue
5.6B
What is the Gross Margin of Shanghai Henlius Biotech Inc?

Based on Shanghai Henlius Biotech Inc's most recent financial statements, the company has Gross Margin of 73.2%.